|
|
非肝硬化肝癌相关的血清学生物标志物：在临床诊断及预后中的应用前景
|
Abstract:
肝细胞癌是一种高度恶性的肿瘤，目前肝细胞癌患者的死亡率排名在所有癌症中占第三位。尤其在非肝硬化背景下，其早期诊断和预后评估更具挑战性。随着非肝硬化肝癌患病率的增加，早期诊断对于全面治疗具有重要意义。早期诊断可以提高患者的生存率和治疗成功率。因此，对于非肝硬化肝癌患者，识别和监测病因和风险因素对于早期诊断和治疗至关重要。本文综述了非肝硬化肝癌的临床特征，并重点讨论了非肝硬化肝癌患者的血清学标志物及其组合的应用价值，旨在为肝癌患者的早期诊断和预后判断提供参考。
Hepatocellular carcinoma (HCC) is a highly malignant tumor, and the mortality rate of HCC patients currently ranks third out of all cancers. Especially in the non-cirrhotic setting, its early diagnosis and prognosis evaluation are more challenging. With the increasing prevalence of non-cirrhotic HCC, early diagnosis is important for comprehensive treatment. Early diagnosis can improve patient survival rates and treatment success rates. Therefore, identification and monitoring of etiology and risk factors are crucial for early diagnosis and treatment. This review summarizes the clinical features of non-cirrhotic HCC and focuses on the application value of serological markers and their combinations in non-cirrhotic HCC patients, aiming to provide reference for early diagnosis and prognosis of HCC patients.
| [1] | Siegel, R.L., Giaquinto, A.N. and Jemal, A. (2024) Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12-49. https://doi.org/10.3322/caac.21820 |
| [2] | 原发性肝癌诊疗指南(2024年版) [J]. 中国实用外科杂志, 2024, 44(4): 361-386. |
| [3] | Pinyopornpanish, K., Al-Yaman, W., Dasarathy, S., Romero-Marrero, C. and McCullough, A. (2021) Hepatocellular Carcinoma in Patients without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival. Digestive Diseases and Sciences, 67, 2677-2687. https://doi.org/10.1007/s10620-021-07048-5 |
| [4] | Schütte, K., Schulz, C., Poranzke, J., Antweiler, K., Bornschein, J., Bretschneider, T., et al. (2014) Characterization and Prognosis of Patients with Hepatocellular Carcinoma (HCC) in the Non-Cirrhotic Liver. BMC Gastroenterology, 14, Article No. 117. https://doi.org/10.1186/1471-230x-14-117 |
| [5] | Yen, Y., Cheng, Y., Wang, J., Lin, C. and Wang, C. (2021) Characteristics and Etiologies of Hepatocellular Carcinoma in Patients without Cirrhosis: When East Meets West. PLOS ONE, 16, e0244939. https://doi.org/10.1371/journal.pone.0244939 |
| [6] | Beudeker, B.J.B., Guha, R., Stoyanova, K., IJzermans, J.N.M., de Man, R.A., Sprengers, D., et al. (2024) Cryptogenic Non-Cirrhotic HCC: Clinical, Prognostic and Immunologic Aspects of an Emerging HCC Etiology. Scientific Reports, 14, Article No. 4302. https://doi.org/10.1038/s41598-024-52884-w |
| [7] | Ding, J., Liu, H., Zhang, X., Zhao, N., Peng, Y., Shi, J., et al. (2024) Integrative Multiomic Analysis Identifies Distinct Molecular Subtypes of NAFLD in a Chinese Population. Science Translational Medicine, 16, eadh9940. https://doi.org/10.1126/scitranslmed.adh9940 |
| [8] | Dong, Y., Wang, W., Lee, W.J., Meloni, M.F., Clevert, D., Chammas, M.C., et al. (2022) Hepatocellular Carcinoma in the Non-Cirrhotic Liver. Clinical Hemorheology and Microcirculation, 80, 423-436. https://doi.org/10.3233/ch-211309 |
| [9] | Perisetti, A., Goyal, H., Yendala, R., Thandassery, R.B. and Giorgakis, E. (2021) Non-cirrhotic Hepatocellular Carcinoma in Chronic Viral Hepatitis: Current Insights and Advancements. World Journal of Gastroenterology, 27, 3466-3482. https://doi.org/10.3748/wjg.v27.i24.3466 |
| [10] | Prabhakar, T., Kaushal, K., Prasad, M., Gupta, E., Sood, A., Jain, A.K., et al. (2023) Etiologic Fractions in Patients of Hepatocellular Carcinoma in India with and without a Background of Cirrhosis: A Multi-Centric Study. Hepatology International, 17, 745-752. https://doi.org/10.1007/s12072-023-10498-w |
| [11] | Winston, C.B., Schwartz, L.H., Fong, Y., Blumgart, L.H. and Panicek, D.M. (1999) Hepatocellular Carcinoma: MR Imaging Findings in Cirrhotic Livers and Noncirrhotic Livers. Radiology, 210, 75-79. https://doi.org/10.1148/radiology.210.1.r99ja1975 |
| [12] | Di Martino, M., Saba, L., Bosco, S., Rossi, M., Miles, K.A., Di Miscio, R., et al. (2014) Hepatocellular Carcinoma (HCC) in Non-Cirrhotic Liver: Clinical, Radiological and Pathological Findings. European Radiology, 24, 1446-1454. https://doi.org/10.1007/s00330-014-3173-2 |
| [13] | Engstrand, J., Stål, P., Gilg, S., Jansson, A. and Strömberg, C. (2023) Hepatocellular Carcinoma in Cirrhotic versus Non-Cirrhotic Liver: Treatment and Survival Differences in a Nationwide Cohort. Scandinavian Journal of Surgery, 113, 120-130. https://doi.org/10.1177/14574969231220179 |
| [14] | Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., et al. (2023) Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). Liver Cancer, 12, 405-444. https://doi.org/10.1159/000530495 |
| [15] | Leung, C. (2015) Characteristics of Hepatocellular Carcinoma in Cirrhotic and Non-Cirrhotic Non-Alcoholic Fatty Liver Disease. World Journal of Gastroenterology, 21, 1189-1196. https://doi.org/10.3748/wjg.v21.i4.1189 |
| [16] | Lee, D.H. and Lee, J.M. (2017) Primary Malignant Tumours in the Non-Cirrhotic Liver. European Journal of Radiology, 95, 349-361. https://doi.org/10.1016/j.ejrad.2017.08.030 |
| [17] | Pastras, P., Zazas, E., Kalafateli, M., Aggeletopoulou, I., Tsounis, E.P., Kanaloupitis, S., et al. (2024) Predictive Risk Factors and Scoring Systems Associated with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B. Cancers, 16, Article No. 2521. https://doi.org/10.3390/cancers16142521 |
| [18] | Schmelzle, M., Krenzien, F., Schöning, W. and Pratschke, J. (2018) Therapie des hepatozellulären Karzinoms in der zirrhotischen und nicht-zirrhotischen Leber. Der Chirurg, 89, 851-857. https://doi.org/10.1007/s00104-018-0690-6 |
| [19] | Taura, K., Ikai, I., Hatano, E., Yasuchika, K., Nakajima, A., Tada, M., et al. (2007) Influence of Coexisting Cirrhosis on Outcomes after Partial Hepatic Resection for Hepatocellular Carcinoma Fulfilling the Milan Criteria: An Analysis of 293 Patients. Surgery, 142, 685-694. https://doi.org/10.1016/j.surg.2007.05.009 |
| [20] | Lubrano, J., Huet, E., Tsilividis, B., François, A., Goria, O., Riachi, G., et al. (2007) Long‐Term Outcome of Liver Resection for Hepatocellular Carcinoma in Noncirrhotic Nonfibrotic Liver with No Viral Hepatitis or Alcohol Abuse. World Journal of Surgery, 32, 104-109. https://doi.org/10.1007/s00268-007-9291-0 |
| [21] | Trevisani, F., Frigerio, M., Santi, V., Grignaschi, A. and Bernardi, M. (2010) Hepatocellular Carcinoma in Non-Cirrhotic Liver: A Reappraisal. Digestive and Liver Disease, 42, 341-347. https://doi.org/10.1016/j.dld.2009.09.002 |
| [22] | Gawrieh, S., Dakhoul, L., Miller, E., Scanga, A., deLemos, A., Kettler, C., et al. (2019) Characteristics, Aetiologies and Trends of Hepatocellular Carcinoma in Patients without Cirrhosis: A United States Multicentre Study. Alimentary Pharmacology & Therapeutics, 50, 809-821. https://doi.org/10.1111/apt.15464 |
| [23] | Witjes, C.D.M., Polak, W.G., Verhoef, C., Eskens, F.A.L.M., Dwarkasing, R.S., Verheij, J., et al. (2012) Increased Alpha-Fetoprotein Serum Level Is Predictive for Survival and Recurrence of Hepatocellular Carcinoma in Non-Cirrhotic Livers. Digestive Surgery, 29, 522-528. https://doi.org/10.1159/000348669 |
| [24] | Shin, J., Yu, J.H., Jin, Y. and Lee, J. (2021) Incidence and Clinical Features of Hepatitis C Virus-Associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-Endemic Area. Journal of Liver Cancer, 21, 34-44. https://doi.org/10.17998/jlc.21.1.34 |
| [25] | Cui, S., Yu, X. and Qu, X. (2016) Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma. Cancer Investigation, 34, 459-464. https://doi.org/10.1080/07357907.2016.1227445 |
| [26] | Poté, N., Cauchy, F., Albuquerque, M., Voitot, H., Belghiti, J., Castera, L., et al. (2015) Performance of PIVKA-II for Early Hepatocellular Carcinoma Diagnosis and Prediction of Microvascular Invasion. Journal of Hepatology, 62, 848-854. https://doi.org/10.1016/j.jhep.2014.11.005 |
| [27] | Wang, C. (2005) Usefulness of Serum Des-γ-Carboxy Prothrombin in Detection of Hepatocellular Carcinoma. World Journal of Gastroenterology, 11, 6115-6119. https://doi.org/10.3748/wjg.v11.i39.6115 |
| [28] | Kudo, A., Shinoda, M., Ariizumi, S., Kumamoto, T., Katayama, M., Otsubo, T., et al. (2020) Des-Gamma-Carboxy Prothrombin Affects the Survival of HCC Patients with Marginal Liver Function and Curative Treatment: ACRoS1402. Journal of Cancer Research and Clinical Oncology, 146, 2949-2956. https://doi.org/10.1007/s00432-020-03270-2 |
| [29] | Gurbuz, I. and Chiquet-Ehrismann, R. (2015) CCN4/WISP1 (WNT1 Inducible Signaling Pathway Protein 1): A Focus on Its Role in Cancer. The International Journal of Biochemistry & Cell Biology, 62, 142-146. https://doi.org/10.1016/j.biocel.2015.03.007 |
| [30] | Chiang, K., Yeh, C., Chung, L., Feng, T., Sun, C., Chen, M., et al. (2015) WNT-1 Inducible Signaling Pathway Protein-1 Enhances Growth and Tumorigenesis in Human Breast Cancer. Scientific Reports, 5, Article No. 8686. https://doi.org/10.1038/srep08686 |
| [31] | Wang, Q.Y., Feng, Y.J. and Ji, R. (2020) High Expression of WISP1 Promotes Metastasis and Predicts Poor Prognosis in Hepatocellular Carcinoma. European Review for Medical and Pharmacological Sciences, 24, 10445-10451. |
| [32] | Dropmann, A., Alex, S., Schorn, K., Tong, C., Caccamo, T., Godoy, P., et al. (2024) The TGF-β1 Target WISP1 Is Highly Expressed in Liver Cirrhosis and Cirrhotic HCC Microenvironment and Involved in Pro-and Anti-Tumorigenic Effects. Biochemical and Biophysical Research Communications, 732, Article ID: 150409. https://doi.org/10.1016/j.bbrc.2024.150409 |
| [33] | Pistoia, V., Morandi, F., Pezzolo, A., Raffaghello, L. and Prigione, I. (2012) MYCN: From Oncoprotein to Tumor-Associated Antigen. Frontiers in Oncology, 2, Article No. 174. https://doi.org/10.3389/fonc.2012.00174 |
| [34] | Qin, X., Shirakami, Y., Honda, M., Yeh, S., Numata, K., Lai, Y., et al. (2024) Serum MYCN as a Predictive Biomarker of Prognosis and Therapeutic Response in the Prevention of Hepatocellular Carcinoma Recurrence. International Journal of Cancer, 155, 582-594. https://doi.org/10.1002/ijc.34893 |
| [35] | Yasukawa, K., Liew, L.C., Hagiwara, K., Hironaka‐Mitsuhashi, A., Qin, X., Furutani, Y., et al. (2020) MicroRNA‐493‐5p‐Mediated Repression of the mycn Oncogene Inhibits Hepatic Cancer Cell Growth and Invasion. Cancer Science, 111, 869-880. https://doi.org/10.1111/cas.14292 |
| [36] | Peach, C.J., Mignone, V.W., Arruda, M.A., Alcobia, D.C., Hill, S.J., Kilpatrick, L.E., et al. (2018) Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. International Journal of Molecular Sciences, 19, Article No. 1264. https://doi.org/10.3390/ijms19041264 |
| [37] | 蓝雪灵, 黄燕妮, 朱敏敏, 等. 抗VEGF及其受体分子靶向药物治疗肝癌机制的研究进展[J]. 中国临床药理学与治疗学, 2024, 29(6): 707-714. |
| [38] | Lacin, S. and Yalcin, S. (2020) The Prognostic Value of Circulating VEGF-A Level in Patients with Hepatocellular Cancer. Technology in Cancer Research & Treatment, 19, 1-8. https://doi.org/10.1177/1533033820971677 |
| [39] | Lv, K., Yu, S., Wang, Y., Zhang, S., Li, W., Hou, J., et al. (2024) Cancer-Associated Fibroblasts Promote the Progression and Chemoresistance of HCC by Inducing IGF-1. Cellular Signalling, 124, Article ID: 111378. https://doi.org/10.1016/j.cellsig.2024.111378 |
| [40] | 马旸, 崔东倩, 韩陈陈, 等. IGF-1通过激活EGR1诱导肝细胞癌的迁移和侵袭[J]. 安徽医科大学学报, 2019, 54(11): 1750-1755. |
| [41] | Su, W., Lee, K., Yeh, Y., Soon, M., Wang, C., Yu, M., et al. (2010) Association of Circulating Insulin‐Like Growth Factor 1 with Hepatocellular Carcinoma: One Cross‐Sectional Correlation Study. Journal of Clinical Laboratory Analysis, 24, 195-200. https://doi.org/10.1002/jcla.20320 |
| [42] | Kaseb, A.O., Xiao, L., Hassan, M.M., et al. (2014) Development and Validation of Insulin-Like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma. JNCI: Journal of the National Cancer Institute, 106, dju088. |
| [43] | Lacin, S., Yalcin, S., Karakas, Y., Hassan, M.M., Amin, H., Mohamed, Y.I., et al. (2020) Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. Journal of Hepatocellular Carcinoma, 7, 143-153. https://doi.org/10.2147/jhc.s258930 |
| [44] | Kaseb, A.O., Morris, J.S., Hassan, M.M., Siddiqui, A.M., Lin, E., Xiao, L., et al. (2011) Clinical and Prognostic Implications of Plasma Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma. Journal of Clinical Oncology, 29, 3892-3899. https://doi.org/10.1200/jco.2011.36.0636 |
| [45] | Toyoda, H., Kumada, T., Osaki, Y., Oka, H., Urano, F., Kudo, M., et al. (2006) Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers. Clinical Gastroenterology and Hepatology, 4, 1528-1536. https://doi.org/10.1016/j.cgh.2006.09.021 |
| [46] | Olbrich, A., Niemeyer, J., Seiffert, H., Ebel, S., Gros, O., Lordick, F., et al. (2024) The GALAD Score and the BALAD-2 Score Correlate with Transarterial and Systemic Treatment Response and Survival in Patients with Hepatocellular Carcinoma. Journal of Cancer Research and Clinical Oncology, 150, Article No. 81. https://doi.org/10.1007/s00432-023-05526-z |
| [47] | Fox, R., Berhane, S., Teng, M., Cox, T., Tada, T., Toyoda, H., et al. (2014) Biomarker-Based Prognosis in Hepatocellular Carcinoma: Validation and Extension of the BALAD Model. British Journal of Cancer, 110, 2090-2098. https://doi.org/10.1038/bjc.2014.130 |
| [48] | Chan, S.L., Mo, F., Johnson, P., Li, L., Tang, N., Loong, H., et al. (2015) Applicability of BALAD Score in Prognostication of Hepatitis B-Related Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 30, 1529-1535. https://doi.org/10.1111/jgh.13005 |
| [49] | He, H., Ji, B., Jia, Z., Zhang, Y., Wang, X., Tao, X., et al. (2021) A Practical Model Is Equivalent to the BALAD or BALAD-2 Score in Predicting Long-Term Survival after Hepatectomy in Chinese Patients with Hepatocellular Carcinoma. Journal of Cancer, 12, 1474-1482. https://doi.org/10.7150/jca.51593 |
| [50] | Wongjarupong, N., Negron-Ocasio, G.M., Mara, K.C., Prasai, K., Abdallah, M.A., Ahn, K.S., et al. (2021) BALAD and BALAD-2 Predict Survival of Hepatocellular Carcinoma Patients: A North American Cohort Study. HPB, 23, 762-769. https://doi.org/10.1016/j.hpb.2020.09.014 |
| [51] | Sterling, R.K., Lissen, E., Clumeck, N., Sola, R., Correa, M.C., Montaner, J., et al. (2006) Development of a Simple Noninvasive Index to Predict Significant Fibrosis in Patients with HIV/HCV Coinfection. Hepatology, 43, 1317-1325. https://doi.org/10.1002/hep.21178 |
| [52] | Johnson, P.J., Kalyuzhnyy, A., Boswell, E. and Toyoda, H. (2024) Progression of Chronic Liver Disease to Hepatocellular Carcinoma: Implications for Surveillance and Management. BJC Reports, 2, Article No. 39. https://doi.org/10.1038/s44276-024-00050-0 |
| [53] | Lu, S., Sun, H., Zhou, Y., Luo, X., Liu, S., Zhou, W., et al. (2024) Prognosis of Patients with Hepatocellular Carcinoma Treated with TACE: A New Score Combining Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin. Journal of Hepatocellular Carcinoma, 11, 1979-1992. https://doi.org/10.2147/jhc.s481393 |
